Title
Category
Credits
Event date
Cost
Heart Failure at the Crossroads: Early Recognition and Proactive Management
  • Disease management
  • 1.25 ACPE - Pharmacists
  • 1.25 ACPE - Pharmacy Technicians
  • 1.25 AMA - Physicians
  • 1.25 ANCC - Nurses
  • 1.25 APA - Psychologists
  • 1.25 Attendance - General Attendance
  • 1.25 ASWB - Social Workers
$0.00
Heart failure remains a leading cause of hospitalization and mortality. This session focuses on recognizing early signs, diagnostic tools, and evidence-based strategies to optimize care, improve patient quality of life, and reduce readmissions.
Health Equity Foundations: Ensuring No One Is Left Behind
  • Health equity
  • 0.75 ACPE - Pharmacists
  • 0.75 ACPE - Pharmacy Technicians
  • 0.75 ADA - CERP (Dentists/Allied Dental Staff)
  • 0.75 AMA - Physicians
  • 0.75 ANCC - Nurses
  • 0.75 Attendance - General Attendance
  • 0.75 CCMC - General - Case Managers
  • 0.75 CDR - Dietitians
  • 0.75 COPE - Optometrists
$0.00
This on-demand activity introduces health equity concepts, explores root causes of disparities, and provides frameworks for addressing social drivers of health and health-related social needs. By the end, learners will gain practical tools to identify inequities and integrate equity principles into daily work to improve outcomes and organizational value.
GLP-1 Agonists in Practice: A New Era in Obesity and Diabetes Management
  • Disease management
  • Wellness
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 ASWB - Social Workers
$0.00
GLP-1 receptor agonists have reshaped the landscape of obesity and type 2 diabetes management, offering benefits beyond glycemic control. This session explores their mechanisms, clinical applications, and emerging evidence on their implications for broader metabolic care and in the treatment of obesity-related conditions such as obstructive sleep apnea.
Gene Therapy in the Genomic Era: Promise, Progress and Patient Impact
  • Disease management
  • 1.25 ACPE - Pharmacists
  • 1.25 ACPE - Pharmacy Technicians
  • 1.25 AMA - Physicians
  • 1.25 ANCC - Nurses
  • 1.25 APA - Psychologists
  • 1.25 Attendance - General Attendance
  • 1.25 ASWB - Social Workers
$0.00
Gene therapy technologies are revolutionizing treatment for genetic diseases. This session explores the science, clinical applications, and patient perspectives, with a focus on sickle cell disease and emerging technologies like CRISPR.
COPD in 2025: Early Detection, Diagnostic Precision, and Emerging Therapies
  • Disease management
  • 1.25 ACPE - Pharmacists
  • 1.25 ACPE - Pharmacy Technicians
  • 1.25 AMA - Physicians
  • 1.25 ANCC - Nurses
  • 1.25 APA - Psychologists
  • 1.25 Attendance - General Attendance
  • 1.25 ASWB - Social Workers
$0.00
This session explores the latest updates in the diagnosis and management of chronic obstructive pulmonary disease (COPD) as outlined in the 2025 GOLD Report. Early case finding, refined spirometry protocols and novel therapeutic options are discussed, along with the importance of pre-bronchodilator spirometry, strategies for early detection in at-risk populations, and the integration of new treatments into updated treatment algorithms.
Facing Dementia: Early Diagnosis, Communication and Compassionate Care
  • Disease management
  • 0.75 ACPE - Pharmacists
  • 0.75 ACPE - Pharmacy Technicians
  • 0.75 AMA - Physicians
  • 0.75 ANCC - Nurses
  • 0.75 APA - Psychologists
  • 0.75 Attendance - General Attendance
  • 0.75 ASWB - Social Workers
$0.00
Dementia care poses growing challenges in health care, requiring early recognition, accurate diagnosis, and compassionate, evidence-based care. This activity clarifies distinctions between dementia and mild cognitive impairment, reviews common subtypes, and highlights core strategies for improving care delivery and enhancing support for patients and caregivers.
Fatty Liver Disease: The Silent Epidemic
  • Disease management
  • Transplantation
  • 1.25 ACPE - Pharmacists
  • 1.25 ACPE - Pharmacy Technicians
  • 1.25 AMA - Physicians
  • 1.25 ANCC - Nurses
  • 1.25 APA - Psychologists
  • 1.25 Attendance - General Attendance
  • 1.25 ASWB - Social Workers
$0.00
This presentation reviews the latest evidence-based strategies for identifying, diagnosing and managing non-alcoholic fatty liver disease (NAFLD), now recognized as metabolic dysfunction-associated steatotic liver disease (MASLD). The progressive form of this disease, non-alcoholic steatohepatitis (NASH), is on track to become the leading cause of liver transplantation in the United States. Learn about current guidelines, risk-stratification tools, and emerging therapies, and gain insights to improve early detection and optimize patient outcomes.
Atrial Fibrillation: Diagnosis and Initial Management for the Primary Care Provider
  • Cardiology
  • Disease management
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 Attendance - General Attendance
$0.00
This on-demand webcast aims to equip primary care providers with the knowledge and tools necessary for the early identification and management of atrial fibrillation (AFib). Participants will review the epidemiology and risk factors associated with AFib, explore the clinical decision-making process for rate versus rhythm control, and apply current evidence-based guidelines for stroke prevention. Emphasis will be placed on practical approaches to risk stratification, shared decision-making, and optimizing long-term outcomes in the primary care setting.
Chronic Kidney Disease, Metabolic and Cardiovascular Disease: Insights into Present and Future Treatment
  • Disease management
  • 0.75 ACPE - Pharmacists
  • 0.75 ACPE - Pharmacy Technicians
  • 0.75 AMA - Physicians
  • 0.75 ANCC - Nurses
  • 0.75 Attendance - General Attendance
  • 0.75 CCMC - General - Case Managers
  • 0.75 CDR - Dietitians
  • 0.75 ASWB - Social Workers
$0.00
This activity examines current data about chronic kidney disease (CKD), including its health outcomes and relationships with cardiovascular and metabolic disease. Treatment regimens aimed at delaying progression and their outcomes are reviewed, along with current knowledge regarding the pathophysiologic and genetic basis of this disease. Areas of emerging interest in research on potential new treatments targeting the causes of CKD are discussed, including genomic analysis, and their relevance to clinical care.
The Challenging Journey to Diagnosis: A Personal Experience Panel
  • Disease management
  • Rare diseases
  • 0.75 ACPE - Pharmacists
  • 0.75 ACPE - Pharmacy Technicians
  • 0.75 AMA - Physicians
  • 0.75 ANCC - Nurses
  • 0.75 Attendance - General Attendance
  • 0.75 CCMC - General - Case Managers
  • 0.75 CDR - Dietitians
  • 0.75 ASWB - Social Workers
$0.00
This presentation exams the challenges surrounding rare-disease diagnosis and treatment, delving further into the significant impact of the diagnostic odyssey on adults, children, and their families as they seek care for their rare conditions. A panel of individuals speak about the challenges of their own rare-disease odysseys and provide insight into the pronounced effects their prolonged and necessary diagnostic pursuits have had on their personal lives, finances, and physical and mental health.

Pages